To further support the finding that CXCR4 hyperactivation potentiates oncogenic programs, we used the Cancer Gene Census [42] and human B-cell lymphoma datasets [27, 28] for cross-species validation. This evidence concerns the gene CXCR4 and B-cell non-Hodgkin lymphoma.